Accessibility Menu
Curis Stock Quote

Curis (NASDAQ: CRIS)

$1.59
(0.6%)
+0.01
Price as of October 21, 2025, 3:55 p.m. ET

KEY DATA POINTS

Current Price
$1.58
Daily Change
(0.6%) +$0.01
Day's Range
$1.54 - $1.61
Previous Close
$1.58
Open
$1.61
Beta
0.90
Volume
48,299
Average Volume
69,335
Market Cap
19.7M
Market Cap / Employee
$1.58M
52wk Range
$1.02 - $5.38
Revenue
-
Gross Margin
0.98%
Dividend Yield
N/A
EPS
-$4.88
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Curis Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CRIS-70.36%-93.31%-41.77%-100%
S&P+15.06%+95.03%+14.29%+368%

Curis Company Info

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$2.75M8.0%
Gross Profit$2.69M8.9%
Gross Margin97.89%0.8%
Market Cap$24.27M-40.3%
Market Cap / Employee$0.71M0.0%
Employees34-30.6%
Net Income-$8.59M27.2%
EBITDA-$8.21M34.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$10.14M1.4%
Accounts Receivable$2.75M8.1%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$23.85M-24.9%
Short Term Debt$8.62M-15.3%

Ratios

Q2 2025YOY Change
Return On Assets-97.73%-27.1%
Return On Invested Capital-74.54%-16.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$8.01M28.1%
Operating Free Cash Flow-$8.01M28.1%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-45.86-2.11-2.97-3.67-185.47%
Price to Sales3.122.151.592.57-34.99%
Price to Tangible Book Value-3.29-1.04-1.19-1.56-101.84%
Enterprise Value to EBITDA-4.80-4.52-3.16-6.2945.79%
Return on Equity-372.7%-436.2%-634.7%-2951.2%1323.74%
Total Debt$39.25M$37.13M$34.35M$32.47M-22.55%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.